Centessa Pharma rises on positive data from hemophilia drug study

Centessa Pharmaceuticals

09/09/2021 14:29

(Repeats with no change to headline and text)
    ** Shares of biopharmaceutical co  CNTA.O  up 17.8% at $24.8
premarket - among top pct gainers on the Nasdaq
    ** Co set to open at its highest in over two months after
announcing positive top-line data from proof-of-concept study of
SerpinPC, its drug to treat severe hemophilia  urn:newsml:reuters.com:*:nGNE82XGhK
    ** Hemophilia is a bleeding disorder in which blood does not
clot properly
    ** SerpinPC was well-tolerated, co said, adding side effects
were only observed in one subject with a history of skin
disorder who discontinued treatment due to a reaction at the
injection site
    ** CNTA said SerpinPC reduced annual bleeding rate by 88% in
the highest dose cohort in the last 12 weeks of treatment 
    ** Bleeding rate reductions were similar in patients with
hemophilia A and hemophilia B, co said
    ** We are eager to move SerpinPC into a global development
plan - Chief Medical Officer 
    ** Up to Wednesday's close, CNTA up ~4% since market debut
in May

 (Reporting by Sohini Podder in Bengaluru)
 ((sohini.podder@thomsonreuters.com))